NUCLIDIUM
HQ - Kanton Basel-Stadt
Summary
NUCLIDIUM AG is a clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer.
Deals Overview
Total Deals1
Valued Deals1
Total Value£ 72 M
Avg. Deal Size£ 72 M
All rights reserved. Copyright © 2025 Datasite
